Last reviewed · How we verify
OPC-262
OPC-262 is a selective and potent inhibitor of the sphingosine-1-phosphate receptor 1 (S1PR1).
OPC-262 is a selective and potent inhibitor of the sphingosine-1-phosphate receptor 1 (S1PR1). Used for Relapsing forms of multiple sclerosis.
At a glance
| Generic name | OPC-262 |
|---|---|
| Sponsor | Kyowa Kirin Co., Ltd. |
| Drug class | S1PR1 inhibitor |
| Target | S1PR1 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting S1PR1, OPC-262 is expected to reduce the number of lymphocytes in the blood and lymphoid tissues, thereby exerting anti-inflammatory effects. This mechanism is thought to be beneficial in the treatment of autoimmune diseases such as multiple sclerosis.
Approved indications
- Relapsing forms of multiple sclerosis
Common side effects
- Headache
- Nausea
- Diarrhea
Key clinical trials
- A Phase 2 Study of OPC-262 in Patients With Type 2 Diabetes (PHASE2)
- A Study of OPC-262 in Patients With Type 2 Diabetes (PHASE2, PHASE3)
- A Study of OPC-262 in Patients With Type 2 Diabetes (PHASE3)
- Along-term Study of OPC-262 in Patients With Type 2 Diabetes (PHASE3)
- A Phase 3 Study of OPC-262 in Patients With Type 2 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OPC-262 CI brief — competitive landscape report
- OPC-262 updates RSS · CI watch RSS
- Kyowa Kirin Co., Ltd. portfolio CI